Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features

R J Rebello; R G Bristow

doi:10.1016/j.clon.2019.11.002

Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features

Research output: Contribution to journal › Article › peer-review

Abstract

Localised prostate cancer (PCa) remains a disease setting where absolute prognostication is difficult, as features that indicate upfront clinical aggression may not be apparent. An individual's prognosis is currently made based on a multimodal assessment of physical and biochemical disease characteristics and this information is used to predict the likelihood of disease progression [1]. Histopathological assessment of biopsied tissue to identify carcinoma-associated Gleason patterns and TNM tumour classification are standard measures of disease severity [2,3].

Original language	English
Journal	Clinical oncology (Royal College of Radiologists (Great Britain))
Early online date	5 Mar 2020
DOIs	https://doi.org/10.1016/j.clon.2019.11.002
Publication status	Published - 2020

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2019.11.002

Cite this

@article{bbdd420641ce42719025fe742e9aab89,

title = "Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features",

abstract = "Localised prostate cancer (PCa) remains a disease setting where absolute prognostication is difficult, as features that indicate upfront clinical aggression may not be apparent. An individual's prognosis is currently made based on a multimodal assessment of physical and biochemical disease characteristics and this information is used to predict the likelihood of disease progression [1]. Histopathological assessment of biopsied tissue to identify carcinoma-associated Gleason patterns and TNM tumour classification are standard measures of disease severity [2,3].",

author = "Rebello, {R J} and Bristow, {R G}",

year = "2020",

doi = "10.1016/j.clon.2019.11.002",

language = "English",

journal = "Clinical oncology (Royal College of Radiologists (Great Britain))",

issn = "0936-6555",

publisher = "W.B. Saunders Co. Ltd",

}

TY - JOUR

T1 - Intermediate Risk Prostate Cancer

T2 - Disease Heterogeneity Linked to Measurable Biological Features

AU - Rebello, R J

AU - Bristow, R G

PY - 2020

Y1 - 2020

N2 - Localised prostate cancer (PCa) remains a disease setting where absolute prognostication is difficult, as features that indicate upfront clinical aggression may not be apparent. An individual's prognosis is currently made based on a multimodal assessment of physical and biochemical disease characteristics and this information is used to predict the likelihood of disease progression [1]. Histopathological assessment of biopsied tissue to identify carcinoma-associated Gleason patterns and TNM tumour classification are standard measures of disease severity [2,3].

AB - Localised prostate cancer (PCa) remains a disease setting where absolute prognostication is difficult, as features that indicate upfront clinical aggression may not be apparent. An individual's prognosis is currently made based on a multimodal assessment of physical and biochemical disease characteristics and this information is used to predict the likelihood of disease progression [1]. Histopathological assessment of biopsied tissue to identify carcinoma-associated Gleason patterns and TNM tumour classification are standard measures of disease severity [2,3].

U2 - 10.1016/j.clon.2019.11.002

DO - 10.1016/j.clon.2019.11.002

M3 - Article

C2 - 32147317

SN - 0936-6555

JO - Clinical oncology (Royal College of Radiologists (Great Britain))

JF - Clinical oncology (Royal College of Radiologists (Great Britain))

ER -

Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this